-

Tandem Diabetes Care Announces Upcoming Conference Presentations

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences:

  • Citi’s 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at 1:00pm Eastern Time (10:00am Pacific Time),
  • TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024 at 1:30pm Eastern Time (10:30am Pacific Time),
  • 2024 Raymond James Institutional Investor Conference on Wednesday, March 6, 2024 at 11:00am Eastern Time (8:00am Pacific Time),
  • Oppenheimer 34th Annual Healthcare MedTech & Services Conference on Tuesday, March 12, 2024 at 1:20pm Eastern Time (10:20am Pacific Time), and
  • Barclays Global Healthcare Conference on Wednesday, March 13, 2024 at 3:35pm Eastern Time (12:35pm Pacific Time).

The Company update presentations will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.

Tandem Diabetes Care, t:slim X2, and Control-IQ are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the US and/or other countries.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and #TandemDiabetes.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.

Contacts

Media Contact:
858-366-6900
media@tandemdiabetes.com

Investor Contact:
858-366-6900
IR@tandemdiabetes.com

Tandem Diabetes Care, Inc.

NASDAQ:TNDM

Release Versions

Contacts

Media Contact:
858-366-6900
media@tandemdiabetes.com

Investor Contact:
858-366-6900
IR@tandemdiabetes.com

Social Media Profiles
More News From Tandem Diabetes Care, Inc.

Tandem Diabetes Care Announces Second Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Sales of $254.6 million worldwide, including $179.3 million in the United States (U.S.) Gross margin of 57%, up 460 basis points compared to second quarter 2025 Pump shipments of more than 33,000 pumps worldwide, including 22,000 pumps in t...

Tandem Diabetes Care Announces Upcoming Conference Presentation

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at Canaccord Genuity’s 46th Annual Growth Conference on Tuesday, August 11, 2026 at 1:30pm Eastern Time (10:30am Pacific Time). The presentation will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabetes Care...

Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets

SAN DIEGO--(BUSINESS WIRE)--The t:slim X2™ insulin pump from Tandem Diabetes Care is now compatible with Abbott’s FreeStyle Libre 3 Plus CGM sensor in five EU countries....
Back to Newsroom